RTP Mobile Logo
Submitted by jwr@researchtop... on Thu, 10/31/2019 - 18:42
 
Track 1: Introduction

Module 1: Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)

Track 2: First-line therapy for a patient with CLL and no del(17p) or TP53 mutation who requires treatment
Track 3: First-line therapy for an elderly patient with CLL and no del(17p) or TP53 mutation
Track 4: Selection of up-front therapy for a patient with del(17p) CLL
Track 5: Role of minimal residual disease (MRD) testing for patients with CLL
Track 6: MRD assessment to guide therapeutic decision-making
Track 7: Management of MRD-positive disease after completion of first-line venetoclax/obinutuzumab

Module 2: Acalabrutinib and Other Promising Strategies Under Investigation

Track 8: Front-line therapy for a patient with CLL and a TP53 mutation
Track 9: Therapeutic approach for a patient with del(17p) CLL who has a history of atrial fibrillation and is receiving anticoagulation therapy
Track 10: Therapeutic approach for a patient who develops atrial fibrillation during therapy with ibrutinib
Track 11: Activity and tolerability of acalabrutinib versus ibrutinib
Track 12: Headaches associated with acalabrutinib
Track 13: Dosing schedule and development of resistance with Bruton tyrosine kinase (BTK) inhibitors

Module 3: Existing and Recently Approved Approaches for Patients with Relapsed/Refractory CLL

Track 14: Second-line therapy for a patient with CLL with an IGHV mutation and no del(17p) or TP53 mutation after disease progression on FCR (fludarabine/cyclophosphamide/rituximab)
Track 15: Choice of second-line therapy for an elderly patient with CLL with an IGHV mutation and no del(17p) or TP53 mutation
Track 16: Creatinine clearance and risk of tumor lysis syndrome (TLS) with venetoclax
Track 17: Management of venetoclax-associated TLS
Track 18: Selection of third-line therapy for a patient with CLL with an IGHV mutation and no del(17p) or TP53 mutation
Track 19: Comparison of the efficacy and tolerability of the PI3 kinase inhibitors duvelisib and idelalisib
Track 20: Use of PI3 kinase inhibitors for patients with relapsed/refractory CLL
 
FACULTY
 
Jennifer R Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
William G Wierda, MD, PhD
DB Lane Cancer Research Distinguished Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Jennifer Woyach, MD
Associate Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
 
MODERATOR
 
Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas